ACL, JNJ Beating 3Q Estimates

Piper Jaffray prefers stocks that have potential for greater upsides, and has thus remained Neutral on both Alcon, Inc.

and Johnson & Johnson

. In the research report, Piper Jaffray writes "For ACL, the company is benefiting from pricing gains, as well as low single digit volume growth. For JNJ, pricing gains are offsetting declines in volume. In spite of upside for both companies, it's important to note that these data only represent US sales, which could be negated by lower OUS volume and pricing cuts. We remain Neutral on both ACL and JNJ for now, despite the recent sell-off, as we prefer stocks in our universe with greater potential for upside." Alcon, Inc. closed yesterday at $167.94 while Johnson & Johnson closed at $62.31.